Top

Published in:

Open Access 01-12-2014 | Review

Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism

Authors: Ilie-Cosmin Stancu, Bruno Vasconcelos, Dick Terwel, Ilse Dewachter

Published in: Molecular Neurodegeneration | Issue 1/2014

Abstract

The amyloid cascade hypothesis has been the prevailing hypothesis in Alzheimer’s Disease research, although the final and most wanted proof i.e. fully successful anti-amyloid clinical trials in patients, is still lacking. This may require a better in depth understanding of the cascade. Particularly, the exact toxic forms of Aβ and Tau, the molecular link between them and their respective contributions to the disease process need to be identified in detail. Although the lack of final proof has raised substantial criticism on the hypothesis per se, accumulating experimental evidence in in vitro models, in vivo models and from biomarkers analysis in patients supports the amyloid cascade and particularly Aβ-induced Tau-pathology, which is the focus of this review. We here discuss available models that recapitulate Aβ-induced Tau-pathology and review some potential underlying mechanisms. The availability and diversity of these models that mimic the amyloid cascade partially or more complete, provide tools to study remaining questions, which are crucial for development of therapeutic strategies for Alzheimer’s Disease.

Available only for authorised users

Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002, 297 (5580): 353-356.PubMed

Spires-Jones TL, Stoothoff WH, de CA, Jones PB, Hyman BT: Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 2009, 32 (3): 150-159.PubMed

Perrin RJ, Fagan AM, Holtzman DM: Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature. 2009, 461 (7266): 916-922.PubMedCentralPubMed

Selkoe DJ: Alzheimer’s disease. Cold Spring Harb Perspect Biol. 2011, 3 (7): a004457-1-16PubMedCentralPubMed

Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT: Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011, 1 (1): a006189-PubMedCentralPubMed

Tanzi RE, Bertram L: Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005, 120 (4): 545-555.PubMed

Tanzi RE: The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012, 2 (10): a006296-1-10PubMedCentralPubMed

Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, et al: Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998, 393 (6686): 702-705.PubMed

Brunden KR, Trojanowski JQ, Lee VM: Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov. 2009, 8 (10): 783-793.PubMedCentralPubMed

10.

Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F: A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004, 113 (10): 1456-1464.PubMedCentralPubMed

11.

Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M: Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999, 286 (5440): 735-741.PubMed

12.

De SB, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von FK, van LF: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998, 391 (6665): 387-390.

13.

De SB, Iwatsubo T, Wolfe MS: Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med. 2012, 2 (1): a006304-

14.

Dewachter I, Van LF: Secretases as targets for the treatment of Alzheimer’s disease: the prospects. Lancet Neurol. 2002, 1 (7): 409-416.PubMed

15.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999, 400 (6740): 173-177.PubMed

16.

Schenk D, Basi GS, Pangalos MN: Treatment strategies targeting amyloid beta-protein. Cold Spring Harb Perspect Med. 2012, 2 (9): a006387-PubMedCentralPubMed

17.

St George-Hyslop PH, Morris JC: Will anti-amyloid therapies work for Alzheimer’s disease?. Lancet. 2008, 372 (9634): 180-182.PubMed

18.

Small SA, Duff K: Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron. 2008, 60 (4): 534-542.PubMedCentralPubMed

19.

Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M: Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009, 11 (7): 909-913.PubMedCentralPubMed

20.

Goedert M, Clavaguera F, Tolnay M: The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010, 33 (7): 317-325.PubMed

21.

Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM: Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci. 2013, 33 (3): 1024-1037.PubMedCentralPubMed

22.

Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, Tolnay M: Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. 2013, 110 (23): 9535-9540.PubMedCentralPubMed

23.

Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM: Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013, 80 (2): 402-414.PubMedCentralPubMed

24.

Guo JL, Lee VM: Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014, 20 (2): 130-138.PubMedCentralPubMed

25.

Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, Barker SJ, Foley AC, Thorpe JR, Serpell LC, Miller TM, Grinberg LT, Seeley WW, Diamond MI: Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014, 82 (6): 1271-1288.PubMedCentralPubMed

26.

Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K: Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A. 1993, 90 (16): 7789-7793.PubMedCentralPubMed

27.

Busciglio J, Lorenzo A, Yeh J, Yankner BA: beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995, 14 (4): 879-888.PubMed

28.

Ferreira A, Lu Q, Orecchio L, Kosik KS: Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci. 1997, 9 (3): 220-234.PubMed

29.

Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H: Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998, 31 (4): 317-323.PubMed

30.

Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S: Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 2002, 115 (1): 201-211.PubMed

31.

Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM: Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006, 83 (3): 374-384.PubMed

32.

De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL: Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008, 29 (9): 1334-1347.PubMedCentralPubMed

33.

Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP, Hudspeth B, Chen C, Zhao Y, Vinters HV, Frautschy SA, Cole GM: Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009, 29 (28): 9078-9089.PubMedCentralPubMed

34.

Zempel H, Thies E, Mandelkow E, Mandelkow EM: Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010, 30 (36): 11938-11950.PubMed

35.

Zeng KW, Ko H, Yang HO, Wang XM: Icariin attenuates beta-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology. 2010, 59 (6): 542-550.PubMed

36.

Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ: Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011, 108 (14): 5819-5824.PubMedCentralPubMed

37.

Mairet-Coello G, Courchet J, Pieraut S, Courchet V, Maximov A, Polleux F: The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron. 2013, 78 (1): 94-108.PubMedCentralPubMed

38.

Tackenberg C, Grinschgl S, Trutzel A, Santuccione AC, Frey MC, Konietzko U, Grimm J, Brandt R, Nitsch RM: NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis. 2013, 4: e608-PubMedCentralPubMed

39.

Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van GS, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS: Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012, 482 (7384): 216-220.PubMedCentralPubMed

40.

Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995, 373 (6514): 523-527.PubMed

41.

Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997, 94 (24): 13287-13292.PubMedCentralPubMed

42.

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998, 4 (1): 97-100.PubMed

43.

Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999, 274 (10): 6483-6492.PubMed

44.

Duyckaerts C, Potier MC, Delatour B: Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115 (1): 5-38.PubMedCentralPubMed

45.

Echeverria V, Ducatenzeiler A, Dowd E, Jänne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC: Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the β-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 2004, 129 (3): 583-592.PubMed

46.

Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T: A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci. 2013, 33 (15): 6245-6256.PubMedCentralPubMed

47.

Gotz J, Chen F, Van DJ, Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001, 293 (5534): 1491-1495.PubMed

48.

Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001, 293 (5534): 1487-1491.PubMed

49.

Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004, 43 (3): 321-332.PubMed

50.

Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging. 2003, 24 (8): 1063-1070.PubMed

51.

Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M: Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007, 171 (6): 2012-2020.PubMedCentralPubMed

52.

Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van LF: Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008, 172 (3): 786-798.PubMedCentralPubMed

53.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM: A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol. 2010, 177 (4): 1977-1988.PubMedCentralPubMed

54.

Saul A, Sprenger F, Bayer TA, Wirths O: Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer’s disease. Neurobiol Aging. 2013, 34 (11): 2564-2573.PubMed

55.

Stancu IC, Ris L, Vasconcelos B, Marinangeli C, Goeminne L, Laporte V, Haylani LE, Couturier J, Schakman O, Gailly P, Pierrot N, Kienlen-Campard P, Octave JN, Dewachter I: Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer’s disease. FASEB J. 2014, 28 (6): 2620-2631.PubMed

56.

Heraud C, Goufak D, Ando K, Leroy K, Suain V, Yilmaz Z, De DR, Authelet M, Laporte V, Octave JN, Brion JP: Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice. Neurobiol Dis. 2014, 62: 100-112.PubMed

57.

Chabrier MA, Blurton-Jones M, Agazaryan AA, Nerhus JL, Martinez-Coria H, LaFerla FM: Soluble abeta promotes wild-type tau pathology in vivo. J Neurosci. 2012, 32 (48): 17345-17350.PubMedCentralPubMed

58.

Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H: Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol. 2014, 127 (5): 685-698.PubMed

59.

Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006, 26 (40): 10129-10140.PubMed

60.

Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007, 53 (3): 337-351.PubMed

61.

Deng W, Aimone JB, Gage FH: New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat Rev Neurosci. 2010, 11 (5): 339-350.PubMedCentralPubMed

62.

Price JL, Morris JC: Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999, 45 (3): 358-368.PubMed

63.

Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP: Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease. Neurology. 2002, 59 (3): 398-407.PubMed

64.

Price JL, Morris JC: So what if tangles precede plaques?. Neurobiol Aging. 2004, 25 (6): 721-723.PubMed

65.

Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010, 9 (1): 119-128.PubMedCentralPubMed

66.

Braak H, Del TK: The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011, 121 (2): 171-181.PubMed

67.

Musiek ES, Holtzman DM: Origins of Alzheimer’s disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol. 2012, 25 (6): 715-720.PubMedCentralPubMed

68.

Attems J, Jellinger KA: Amyloid and tau: neither chicken nor egg but two partners in crime!. Acta Neuropathol. 2013, 126 (4): 619-621.PubMed

69.

Braak H, Del TK: Amyloid-beta may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer’s disease: a hypothesis. Acta Neuropathol. 2013, 126 (2): 303-306.PubMed

70.

Braak H, Del TK: Reply: the early pathological process in sporadic Alzheimer’s disease. Acta Neuropathol. 2013, 126 (4): 615-618.PubMed

71.

Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ: Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12 (2): 207-216.PubMedCentralPubMed

72.

Mann DM, Hardy J: Amyloid or tau: the chicken or the egg?. Acta Neuropathol. 2013, 126 (4): 609-613.PubMed

73.

Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82 (4): 239-259.PubMed

74.

Hyman BT, Trojanowski JQ: Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997, 56 (10): 1095-1097.PubMed

75.

Thal DR, Rub U, Orantes M, Braak H: Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002, 58 (12): 1791-1800.PubMed

76.

Jucker M, Walker LC: Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013, 501 (7465): 45-51.PubMedCentralPubMed

77.

Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp JA: Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced toxicity. Proc Natl Acad Sci U S A. 1997, 94 (17): 9412-9416.PubMedCentralPubMed

78.

Wang HY, Lee DH, D’Andrea MR, Peterson PA, Shank RP, Reitz AB: beta-Amyloid(1–42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem. 2000, 275 (8): 5626-5632.PubMed

79.

Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D: Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta. 2000, 1502 (1): 145-157.PubMed

80.

Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL: Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J Neurosci. 2004, 24 (45): 10191-10200.PubMed

81.

Verdier Y, Zarandi M, Penke B: Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer’s disease. J Pept Sci. 2004, 10 (5): 229-248.PubMed

82.

Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL: Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007, 27 (4): 796-807.PubMed

83.

Simakova O, Arispe NJ: The cell-selective neurotoxicity of the Alzheimer’s Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J Neurosci. 2007, 27 (50): 13719-13729.PubMed

84.

Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL: Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009, 106 (10): 4012-4017.PubMedCentralPubMed

85.

Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009, 457 (7233): 1128-1132.PubMedCentralPubMed

86.

Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, Chiesa R, Gobbi M, Salmona M, Forloni G: Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A. 2010, 107 (5): 2295-2300.PubMedCentralPubMed

87.

Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM: Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010, 30 (18): 6367-6374.PubMedCentralPubMed

88.

Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011, 469 (7328): 47-52.PubMedCentralPubMed

89.

Benilova I, De SB: Neuroscience. Promiscuous Alzheimer’s amyloid: yet another partner. Science. 2013, 341 (6152): 1354-1355.PubMed

90.

Kim T, Vidal GS, Djurisic M, William CM, Birnbaum ME, Garcia KC, Hyman BT, Shatz CJ: Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer’s model. Science. 2013, 341 (6152): 1399-1404.PubMed

91.

Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF: Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2009, 29 (27): 8805-8815.PubMedCentralPubMed

92.

Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science. 2002, 298 (5594): 789-791.PubMed

93.

Palop JJ, Mucke L: Synaptic depression and aberrant excitatory network activity in Alzheimer’s disease: two faces of the same coin?. Neuromolecular Med. 2010, 12 (1): 48-55.PubMedCentralPubMed

94.

Ittner LM, Gotz J: Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011, 12 (2): 65-72.PubMed

95.

Malinow R: New developments on the role of NMDA receptors in Alzheimer’s disease. Curr Opin Neurobiol. 2012, 22 (3): 559-563.PubMedCentralPubMed

96.

Mucke L, Selkoe DJ: Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012, 2 (7): a006338-PubMedCentralPubMed

97.

Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005, 8 (8): 1051-1058.PubMed

98.

Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S, Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek L, Herms J, Van Leuven F: Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging. 2009, 30 (2): 241-256.PubMed

99.

Kessels HW, Nabavi S, Malinow R: Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci U S A. 2013, 110 (10): 4033-4038.PubMedCentralPubMed

100.

Hu NW, Nicoll AJ, Zhang D, Mably AJ, O’Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ: mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun. 2014, 5: 3374-PubMedCentralPubMed

101.

Morris M, Maeda S, Vossel K, Mucke L: The many faces of tau. Neuron. 2011, 70 (3): 410-426.PubMedCentralPubMed

102.

Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science. 2007, 316 (5825): 750-754.PubMed

103.

Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L: Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci. 2011, 31 (2): 700-711.PubMedCentralPubMed

104.

Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, Vargas-Caballero M: Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011, 31 (5): 1688-1692.PubMed

105.

Haass C, Mandelkow E: Fyn-tau-amyloid: a toxic triad. Cell. 2010, 142 (3): 356-358.PubMed

106.

Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Van EJ, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010, 142 (3): 387-397.PubMed

107.

Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y: Cleavage of Tau by calpain in Alzheimer’s disease: the quest for the toxic 17 kD fragment. Neurobiol Aging. 2011, 32 (1): 1-14.PubMed

108.

Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM: Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci. 2011, 31 (7): 2511-2525.PubMed

109.

Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, Cui B, Mucke L: Tau reduction prevents Aβ-induced defects in axonal transport. Science. 2010, 330 (6001): 198-PubMedCentralPubMed

110.

Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dröse S, Brandt U, Savaskan E, Czech C, Götz J, Eckert A: Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci. 2009, 106 (47): 20057-20062.PubMedCentralPubMed

111.

Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, Matthews P, Isaac JT, Bortolotto ZA, Wang YT, Collingridge GL: LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron. 2007, 53 (5): 703-717.PubMed

112.

Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, Cho K: Abeta(1–42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci. 2011, 14 (5): 545-547.PubMed

113.

Hurtado DE, Molina-Porcel L, Carroll JC, Macdonald C, Aboagye AK, Trojanowski JQ, Lee VM: Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer’s disease. J Neurosci. 2012, 32 (21): 7392-7402.PubMedCentralPubMed

114.

Li Y, Liu L, Barger SW, Griffin WS: Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci. 2003, 23 (5): 1605-1611.PubMedCentralPubMed

115.

Saez ET, Pehar M, Vargas MR, Barbeito L, Maccioni RB: Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons. J Neurosci Res. 2006, 84 (5): 1098-1106.PubMed

116.

Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W: Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 2011, 2: e167-PubMedCentralPubMed

117.

Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT: Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010, 68 (1): 19-31.PubMedCentralPubMed

118.

Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, LaFerla FM: Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer’s disease model. J Immunol. 2011, 187 (12): 6539-6549.PubMedCentralPubMed

119.

Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, LaFerla FM: Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol. 2011, 178 (6): 2811-2822.PubMedCentralPubMed

120.

Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA, O’Banion MK: Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer’s mouse model. J Neurosci. 2013, 33 (11): 5053-5064.PubMedCentralPubMed

121.

Soto C, Estrada L, Castilla J: Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci. 2006, 31 (3): 150-155.PubMed

122.

Luk KC, Song C, O’Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM: Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009, 106 (47): 20051-20056.PubMedCentralPubMed

123.

Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM: Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011, 72 (1): 57-71.PubMedCentralPubMed

124.

Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM: Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012, 338 (6109): 949-953.PubMedCentralPubMed

125.

Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM: Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012, 209 (5): 975-986.PubMedCentralPubMed

126.

Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM: Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013, 154 (1): 103-117.PubMed

127.

Guo JP, Arai T, Miklossy J, McGeer PL: Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006, 103 (6): 1953-1958.PubMedCentralPubMed

128.

Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D’Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, Kim DY: A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature. 2014, doi:10.1038/nature13800

Title: Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism
Authors: Ilie-Cosmin Stancu
Bruno Vasconcelos
Dick Terwel
Ilse Dewachter
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Molecular Neurodegeneration / Issue 1/2014
Electronic ISSN: 1750-1326
DOI: https://doi.org/10.1186/1750-1326-9-51

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition

U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21

Altered synaptic structure in the hippocampus in a mouse model of Alzheimer’s disease with soluble amyloid-β oligomers and no plaque pathology

Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow

Molecular neurodegeneration: basic biology and disease pathways

Pathogenic polyglutamine expansion length correlates with polarity of the flanking sequences